Dialysis world news

Nxstage Medical, Inc. (NXTM) Discloses SEC Form 4 Insider Selling : Joseph E ... - Money Flow Index PDF Print

Nxstage Medical, Inc. (NXTM) Discloses Insider Transaction. Joseph E Jr Turk , President of Nxstage Medical, Inc. sold 2,500 shares on Aug 4, 2015. The Insider selling transaction was disclosed on Aug 6, 2015 to the Securities and Exchange Commission. The shares were sold at $15.00 per share for a total value of $37,500.00.

NxStage Medical, Inc. (NXTM) shares are expected to touch $21 in the short term. This short term price target has been shared by 4 analysts. However, the standard deviation of short term price estimate has been valued at 4.24. The target price could hit $24 on the higher end and $15 on the lower end. Shares of Nxstage Medical, Inc. rose by 5.99% in the last five trading days and 2.44% for the last 4 weeks. Nxstage Medical, Inc. has dropped 21.23% during the last 3-month period . Year-to-Date the stock performance stands at -18.07%. Currently the company Insiders own 2.3% of Nxstage Medical, Inc. Company shares. In the past six months, there is a change of -5.19% in the total insider ownership. Institutional Investors own 95.4% of Company shares. During last 3 month period, -0.93% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Turk Joseph E Jr, (President) of Nxstage Medical, Inc., had unloaded 2,000 shares at an average price of $13.86 in a transaction dated on July 22, 2015. The total value of the transaction was worth $27,720. Shares of NxStage Medical, Inc. (NXTM) ended Tuesday session in red amid volatile trading. The shares closed down 0.13 points or 0.88% at $14.69 with 678,523 shares getting traded. Post opening the session at $14.87, the shares hit an intraday low of $14.61 and an intraday high of $15.12 and the price vacillated in this range throughout the day. The company has a market cap of $929 million and the number of outstanding shares have been calculated to be 63,238,000 shares. The 52-week high of NxStage Medical, Inc. (NXTM) is $19.63 and the 52-week low is $11.5. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.


Govt. to modernize the ICU of Maligawatte Renal Dialysis and Transplant unit - The Official Government News Portal of Sri Lanka PDF Print


In this hospital both Intensive Care Unit (ICU) and the Isolation Unit are situated inside the residential patient's ward.  As a result, patients who undergo renal transplants are under severe risk of getting infections.


Therefore, to minimize that risk, a proposal made by the.Minister of Health and Indigenous Medicine to renovate the intensive care unit considering it as an urgent requirement so as to keep those patients in the ICU, was approved by the Cabinet of  Ministers at the weekly Cabinet Meeting held last Wednesday (05).


Research and Markets: Global Human Growth Hormone Market Report: 2015 Edition - Business Wire (press release) PDF Print

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/p854qs/global_human) has announced the addition of the "Global Human Growth Hormone Market Report: 2015 Edition" report to their offering.

Pituitary - the master gland of human body is responsible for controlling crucial hormonal secretion, which, in turn, regulates other key aspects of the body such as temperature, growth, thyroid functioning, urination, and production of other hormones. It is a pea sized gland situated at the base of brain and is a major component of human body as it expedites the response towards the surrounding environment and settings.

Any deformity or damage to the pituitary gland can adversely impact the production and activity level of the above mentioned hormones, thereby affecting the body work process and stunting the outcomes especially in the case of growth hormone. Marred pituitary function leads to either over or under secretion of the somatropin that is the growth hormone. Its over secretion causes disfiguration in the body parts like hands, face, feet, etc. whereas, its deficiency impedes the growth of body parts/whole body, thus leading to disease states like dwarfism or gigantism.

It is observed that the growth hormone related problems usually affect children and teenagers, but it is seen to grip adults as well though to a lesser extent. The major factors which vitiate the pituitary operations thus impairing the GH role include kidney malfunction, tumors/cancer especially associated with brain. There are some other unknown causes as well which are termed as idiopathic. Earlier, to deal with these predicaments, growth hormone used to be extracted from the human cadavers but, as time passed and evolution of technology/tools/techniques/R&D took place, the extraction of GH also got altered and many novel innovations and discoveries were made in the respective field.

Nowadays, many leading companies are heavily involved in the R&D process for devising longer acting and sustained release versions of the somatropin which are produced using the recombinant technology. The competition prevalent in the respective industry is heating up day by day. The human growth hormone market is monopolized by a few players viz. Pfizer, NovoNordisk, Eli Lilly, Sandoz and Roche.

The global HGH report discusses the key ongoing trends like global agreement for Long-Acting Human Growth Hormone (HGH-CTP), increasing use of biosimilar version of drugs and continuous growth of recombinant growth hormones market. On the industry development front, the current inclination is towards developing better treatments for Alzheimer's disease and advancements in needle free injections technology. Furthermore, the major factors driving the HGH market include rising cancer and CKD/ESRD cases and increasing healthcare expenditure on worldwide basis. In addition, a few factors posing challenges in front of the HGH industry are the problems in diagnosis of growth hormone deficiency, risks associated with use of recombinant growth hormone therapies and off-label HGH use which, to an extent, are hindering the growth and development of the same.

Key Topics Covered

1. Human Growth Hormone

2. Human Growth Hormone (HGH) Market Analysis

3. Market Dynamics

4. Competitive Landscape

5. Company Profiles

6. Market Outlook

Companies Mentioned

  • Eli Lilly and Company
  • Novo Nordisk
  • Pfizer
  • Roche

For more information visit http://www.researchandmarkets.com/research/p854qs/global_human


Shares of DaVita healthCare Partners Inc. (NYSE:DVA) Sees Large Outflow of Money - Money Flow Index PDF Print

DaVita healthCare Partners Inc. (NYSE:DVA) surged 0.81% during the last session. The last traded price was up 0.65 points at $81.14. The data for the fund flow suggests that the net intraday money flow was $(-9.53) million. The fund value in upticks was recorded to be $22.34 million and in downticks, it was found to be $31.87 million. The up/down ratio for the day was measured to be 0.7. For the week, the shares have seen a percentage change of 2.67%.A block trade of $(-9.15) million in net money flow was also recorded during the day. For the block, the combined worth of upticks was $0 million and that of downticks was $9.15 million. The block tradeoff had the up/down ratio of 0.

DaVita Company has received recommendation from many analysts. Baird upgrades its rating on DaVita healthCare Partners Inc. (NYSE:DVA). The global brokerage major raises the current price target from $75 per share to $95 per share. Analysts at the Baird have a current rating of Outperform on the shares. The shares were previously rated Neutral. The rating by the firm was issued on April 27, 2015. DaVita healthCare Partners Inc. (NYSE:DVA) should head towards $90.2 per share according to 5 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $85 per share. The higher price estimate target is at $96 according to the Analysts. The company shares have rallied 12.59% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $85.17 and one year low was seen on August 7, 2014 at $71.31. The 50-day moving average is $79.91 and the 200 day moving average is recorded at $79.85. S&P 500 has rallied 9.96% during the last 52-weeks. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (Co-Chairman of the Board) of Davita Healthcare Partners Inc., Margolis Robert J had sold 31,400 shares worth of $2,619,074 in a transaction dated June 3, 2015. In this transaction, 31,400 shares were sold at $83.41 per share. DaVita healthCare Partners Inc. (NYSE:DVA) rose 0.81% or 0.65 points on Thursday and made its way into the gainers of the day. After trading began at $80.49 the stock was seen hitting $81.29 as a peak level and $80.49 as the lowest level. The stock ended up at $81.14. The daily volume was measured at 1,514,103 shares. The 52-week high of the share price is $85.17 and the 52-week low is $71.1. The company has a market cap of $17,483 million. DaVita HealthCare Partners Inc., formerly DaVita Inc., is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2011, the Company provided dialysis and administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving a total of approximately 142,000 patients. It also provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the United States. In July 2013, DaVita, a division of DaVita HealthCare Partners Inc announced the acquisition of the dialysis operations of Malaysias Caring Dialysis Centre Group (CDC Group) by DVA (Malaysia) Sdn Bhd.


LA BioMed researcher launches study to examine medication adherence among ... - News-Medical.net PDF Print

Taking medications as prescribed is challenging for many patients, and following doctors' orders regarding medication often varies over time and among different patients. The consequences of failing to follow the prescribed medication regimen range from mild to life-threatening, depending on the medication and the illness or condition being treated.

To help improve patients' adherence to prescribed medication regimens, Jenny Shen, MD, a Los Angeles Biomedical Research Institute (LA BioMed) researcher, is launching a study of medication adherence among patients with dialysis, a life-saving treatment for many Americans with life-threatening end-stage kidney disease. She will be examining why patients follow or don't follow their physicians' orders regarding their doses and the timing of cardiovascular medications. She also will study how the patients' decisions about their medication affect their health.

"We are going to study why variations in medication adherence exist, and if these variations are associated with an increased risk of heart attacks, stroke or death," Dr. Shen said. "We will also be researching to determine if the risks change depending on a patient's race and ethnicity. Results of our research will aid in the development of tools to improve adherence in this patient population, which may improve their health."

She said patients on dialysis take an average of 15 pills per day, far more than most other patients, and their compliance with their medication regimen is below 50%. Patients on dialysis also are more likely to suffer from cardiovascular disease, with 42% dying from a cardiovascular-related cause.

The National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health awarded Dr. Shen $906,054 for her study, entitled "Trajectories of Adherence to Cardiovascular Medications in Patients on Dialysis." This award is for five years.

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)


<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>

Page 21 of 2630
Share |
Copyright © 2021 Global Dialysis. All Rights Reserved.